Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12601 - 12625 of 14373 in total
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene.
Investigational
AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Investigational
Investigational
Investigational
Investigational
Investigational
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Investigational
ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
Investigational
Investigational
Investigational
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
Investigational
Investigational
PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
Investigational
Displaying drugs 12601 - 12625 of 14373 in total